mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer

Harrison Cash, Sujay Shah, Ellen Moore, Andria Caruso, Ravindra Uppaluri, Carter Van Waes, Clint T Allen

Research output: Contribution to journalArticle

Abstract

We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.

Original languageEnglish (US)
Pages (from-to)36400-36417
Number of pages18
JournalOncotarget
Volume6
Issue number34
DOIs
StatePublished - 2015

Fingerprint

Mouth Neoplasms
Mouth
Sirolimus
Growth
Neoplasms
T-Lymphocytes
CD8 Antigens
Tumor Microenvironment
Cell Transplantation
Mitogen-Activated Protein Kinase Kinases
Therapeutics

Keywords

  • Animal models of cancer
  • Head and neck/oral cancers
  • Immunomodulation
  • Inflammation and tumor development
  • Signal transduction pathways

ASJC Scopus subject areas

  • Oncology

Cite this

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. / Cash, Harrison; Shah, Sujay; Moore, Ellen; Caruso, Andria; Uppaluri, Ravindra; Van Waes, Carter; Allen, Clint T.

In: Oncotarget, Vol. 6, No. 34, 2015, p. 36400-36417.

Research output: Contribution to journalArticle

Cash, Harrison ; Shah, Sujay ; Moore, Ellen ; Caruso, Andria ; Uppaluri, Ravindra ; Van Waes, Carter ; Allen, Clint T. / mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. In: Oncotarget. 2015 ; Vol. 6, No. 34. pp. 36400-36417.
@article{b7cc5b0d16f1444ab3bb80bf7c7e191b,
title = "mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer",
abstract = "We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.",
keywords = "Animal models of cancer, Head and neck/oral cancers, Immunomodulation, Inflammation and tumor development, Signal transduction pathways",
author = "Harrison Cash and Sujay Shah and Ellen Moore and Andria Caruso and Ravindra Uppaluri and {Van Waes}, Carter and Allen, {Clint T}",
year = "2015",
doi = "10.18632/oncotarget.5063",
language = "English (US)",
volume = "6",
pages = "36400--36417",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "34",

}

TY - JOUR

T1 - mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer

AU - Cash, Harrison

AU - Shah, Sujay

AU - Moore, Ellen

AU - Caruso, Andria

AU - Uppaluri, Ravindra

AU - Van Waes, Carter

AU - Allen, Clint T

PY - 2015

Y1 - 2015

N2 - We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.

AB - We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.

KW - Animal models of cancer

KW - Head and neck/oral cancers

KW - Immunomodulation

KW - Inflammation and tumor development

KW - Signal transduction pathways

UR - http://www.scopus.com/inward/record.url?scp=84946854648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946854648&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5063

DO - 10.18632/oncotarget.5063

M3 - Article

C2 - 26506415

AN - SCOPUS:84946854648

VL - 6

SP - 36400

EP - 36417

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -